Excellent clinical outcomes can be achieved with neoadjuvant chemoradiation and orthotopic liver transplantation for unresectable cholangiocarcinoma: support for the need of an international transplant protocol

We thank Dr. He et al. for their comments regarding our retrospective study evaluating treatment strategies in the management of hilar and extrahilar cholangiocarcinoma, published in Journal of Gastrointestinal Oncology (1). The combination of neoadjuvant chemoradiation followed by orthotopic liver transplantation via an institutional-based strict protocol/selection process provides the best outcomes for these patients. This has been well validated (2-5). Ultimately, eligibility for this protocol is rigorous: patients may not have metastatic disease, tumor size >3 cm, or medical conditions that would preclude transplant (2,3). Patients with a malignant stricture in the setting of primary sclerosing cholangitis are also eligible (2,3). For several different reasons, approximately 25% of patients who initiate protocol-based therapy become ineligible to proceed with liver transplantation (6). It is important to note that patients with unresectable disease who undergo this protocol may have superior outcomes compared to patients with resectable disease who undergo surgical resection followed by adjuvant therapy (1,6).

He et al. presents an excellent discussion regarding current prospective clinical trials incorporating orthotopic liver transplantation for unresectable hilar cholangiocarcinoma. Collecting prospective clinical data at a national or international scale is the next step to help validate the current protocol of neoadjuvant chemoradiation and liver transplantation for hilar cholangiocarcinoma. While this approach has been well studied in the setting of hilar cholangiocarcinoma, intrahepatic cholangiocarcinoma has previously been a contraindication for liver transplant given its aggressive behavior and poor outcomes (7). We certainly agree with He et al. that this approach warrants further investigation. As He et al. also noted, the prognosis of intrahepatic, hilar, and extrahepatic cholangiocarcinoma could be enhanced further with new targeted agents and immunotherapy, as well as combinations of these novel systemic options with modern radiotherapeutic approaches. These represent active research areas, all to try and improve the currently poor outcomes for this group of patients.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Journal of Gastrointestinal Oncology. The article did not undergo external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-2022-01/coif). TTS reports that he provides strategic and scientific recommendations as a member of the Advisory Board and speaker for Novocure, Inc., and also as a member of the advisory board to Galera Therapeutics, which are not in any way associated with the content presented in this editorial. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work and in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Laughlin BS, Petersen MM, Yu NY, et al. Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies: a single-center experience. J Gastrointest Oncol 2022;13:288-97. [Crossref] [PubMed]
2. Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl Int 2010;23:692-7. [Crossref] [PubMed]
3. Heimbach JK, Gores GJ, Haddock MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis 2004;24:201-7. [Crossref] [PubMed]
4. Tan EK, Rosen CB, Heimbach JK, et al. Living Donor Liver Transplantation for Perihilar Cholangiocarcinoma: Outcomes and Complications. J Am Coll Surg 2020;231:98-110. [Crossref] [PubMed]
5. De Vreede I, Steers JL, Burch PA, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 2000;6:309-16. [Crossref] [PubMed]
6. Sio TT, Martenson JA Jr, Haddock MG, et al. Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma. Am J Clin Oncol 2016;39:271-5. [Crossref] [PubMed]
7. Lee DD, Croome KP, Musto KR, et al. Liver transplantation for intrahepatic cholangiocarcinoma. Liver Transpl 2018;24:634-44. [Crossref] [PubMed]